Category IMMUNOTHERAPY

PIER MARIA FORNASARI
2024-05-25

Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

Combining immune-targeted therapy with chemotherapy improves both progression-free survival and overall survival when compared to those who received regorafenib alone A study(Link is external) (Link opens in new window) led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2024-04-24

FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients

Approval is based on findings from the QUILT 3.032 clinical trial, which was led by UCLA’s Dr. Karim Chamie The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the treatment of

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2021-10-10

CRISPR CAR-T cells can Revolutionize Cancer Treatment

Cancer is the second leading cause of death in the United States, taking half a million lives each year. CAR T technology has successfully harnessed the human immune system to produce awe-inspiring cancer remission rates. CRISPR-mediated genome engineering has enabled new developments in CAR T cells to bypass logistical, technical, and immunological roadblocks, making the

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2021-06-01

A Novel Form of Macrophage-based Immunotherapy Developed by Georgia State University Has the Potential to Revolutionize Cancer Treatment

A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu.  Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2020-02-23

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments. Now, scientists have developed a new metric they believe can help predict whether patients will respond

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2020-02-18

Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

The immune checkpoint inhibitor nivolumab may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients’ lives and the time they

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2020-01-08

Melanoma Immunotherapy Enhanced by Targeting Treg Cell Control Protein

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a new potential strategy for boosting the immune system’s ability to fight cancer.  Studies in gene knockout mice, carried out in collaboration with a team at NYU Langone’s Perlmutter Cancer Center, suggested that a protein known as Siah2 is involved in the control of T

Read More

No Comments InCANCER IMMUNOTHERAPY
PIER MARIA FORNASARI
2019-12-27

Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations

Source Targeted Oncology The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.1,2 Today, cancer immunotherapies, all of which recruit the body’s own immune system to target and eliminate cancer cells,

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2019-11-02

Moffitt Researchers Identify a Mechanism Controlling Tumor Cell Recognition by Immune Cells

Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer Immunology Research, Moffitt Cancer Center researchers, in collaboration with the University of Miami’s Miller School of Medicine, describe a cellular mechanism that controls tumor cell

Read More

No Comments InIMMUNOTHERAPY